Skip to main content
. 2019 Dec 27;112(10):1055–1062. doi: 10.1093/jnci/djz243

Figure 2.

Figure 2.

Per-fill out-of-pocket spending on orally administered anticancer medications pre- and postparity, by plan funding status. A) Tyrosine kinase inhibitors and (B) Immunomodulatory drugs. Source: Authors’ analysis of Health Care Cost Institute Claims, 2008–2017. Per-fill out-of-pocket spending standardized to a 30-day supply equivalent. Dollars were inflation adjusted using the medical component of the Consumer Price Index to 2017 US dollars. Models were adjusted using inverse probability of treatment propensity score weights. Adjusted risk ratio (aRR) for paying more than $100 per fill: aRR chronic myeloid leukemia (CML) = 0.74, 95% confidence interval [CI] = 0.54 to 0.1.01, P = .06; aRR multiple myeloma (MM) = 0.85, 95% CI = 0.68 to 1.06, P = .15. aRR for paying $0 per fill: aRR CML = 4.27, 95% CI = 2.20 to 8.27, P ≤ .001; aRR MM = 1.96, 95% CI = 1.40 to 2.73, P ≤ .001. TKI = tyrosine kinase inhibitor.